排名前五的靶点	数量

SIRT3(NAD依赖性脱乙酰酶sirtuin-3)	1
PTEN(PTEN磷酸水解酶)	1
KEAP1(Kelch样ECH相关蛋白-1)	1
RIPK2(丝氨酸/苏氨酸蛋白激酶RIPK2)	1
AMPK x GLUT-4 x mTOR	1

关联

项与成都中医药大学相关的药物

Vitexin

牡荆素

靶点-

作用机制-

在研机构

National Institute of Pharmaceutical Education And Research (NIPER) [+2]

原研机构

贵州银杏鹰药业有限公司

在研适应症

慢性支气管炎 [+3]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2004-11-22

Gastrodine

天麻素

靶点

GFAP x PI3Ks

作用机制

GFAP抑制剂 [+1]

在研机构

昆药集团股份有限公司 [+4]

原研机构

昆药集团股份有限公司

在研适应症

创伤性脑损伤 [+8]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2001-01-01

Daidzein

黄豆苷元

靶点

PPAR

作用机制

PPAR激动剂

在研机构

Ochanomizu University [+1]

原研机构-

在研适应症

胃溃疡 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期-

274

项与成都中医药大学相关的临床试验

NCT07355751

/ Not yet recruitingN/AIIT

The Effect of Acupuncture Treatment on Cognitive Functions and Brain Networks for Long COVID: a Multimodal Magnetic Resonance Imaging Study

Background of study:
Long COVID(LC) is a prevalent sequalae of SARS-CoV-2 infection and can affect multiple organ systems. Cognitive dysfunction is one of the most common symptoms in LC with 22% prevalence. It can persist for years and significantly reduce patients' quality of life. Brain network is the neural basis underlying human cognitive processes. Diffusion tensor imaging (DTI) and functional magnetic resonance imaging(fMRI) research has revealed that alterations of network characteristics were associated with cognitive impairments across attention, memory, executive function and language in LC. Currently, there is no accepted therapy for cognitive impairment in LC. Acupuncture, as a Traditional Chinese Medicine therapy, has potential to improve cognitive deficits for LC. However, research focusing on the impact of acupuncture on cognitive functions in LC is rare. Additionally, no one has evaluated the mechanism of acupuncture improving cognitive functions in LC.
Objective of the study:
This study aims to assess the effect of acupuncture treatment on cognitive function and explore the central mechanism of acupuncture therapy in improving cognitive function for LC using cognitive assessments, DTI and resting-state fMRI.
Study design:
A prospective, three-armed, randomized controlled trial with DTI and rs-fMRI. Adults with LC will be randomly assigned to acupuncture, sham acupuncture, or waitlist control group in a 1:1:1 ratio, receiving 8-week intervention or waiting. Cognitive function and topological attributes of brain networks will be examined at baseline and 8th week.
Study population:
Patients fulfilling World Health Organization (WHO) criteria for LC will be included in this study.

开始日期2026-05-01

申办/合作机构

成都中医药大学

NCT07357688

/ Not yet recruitingN/AIIT

The Effect of Acupuncture Therapy on Cognitive Function in Post-COVID-19 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Study With Multimodal Magnetic Resonance Imaging

Background of study:
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a common sequela after SARS-CoV-2 infection(COVID-19). Cognitive dysfunction is one of the most common debilitating symptoms in ME/CFS. Currently, standardized therapy for ME/CFS has not been established. Some treatments, such as cognitive behavioral therapy (CBT) and graded exercise therapy (GET), mainly exert effects on physical symptoms, whereas the influence on cognitive problems is not significant. Acupuncture is an important complementary and alternative therapy for ME/CFS. However, However, research focused on the impact of acupuncture on cognitive functions in ME/CFS is rare. Additionally, no study has evaluated the efficacy and mechanism of acupuncture treatment in improving cognitive functions for post-COVID-19 ME/CFS.
Objective of the study:
The first objective of this study is to assess the efficacy of acupuncture treatment in improving cognitive function for post-COVID-19 ME/CFS. The second objective is to explore whether acupuncture improves cognitive ability in patients with post-COVID-19 ME/CFS through modulating hippocampal connectivity and metabolites using multimodal magnetic resonance imaging(MRI).
Study design:
A prospective, three-armed, randomized controlled trial with resting-state functional MRI(rs-fMRI) and magnetic resonance spectroscopy(MRS). Adults with post-COVID-19 ME/CFS will be randomly assigned to acupuncture, sham acupuncture, or waitlist control group in a 1:1:1 ratio, receiving 8-week intervention or waiting. Cognitive functions and resting-state functional connectivity(RSFC) and the levels of metabolites for each hippocampus will be examined at baseline and 8th week.
Study population:
Patients fulfilling 2015 National Academy of Medicine (NAM) criteria for ME/CFS following COVID-19.

开始日期2026-05-01

申办/合作机构

成都中医药大学

NCT07277218

/ Not yet recruitingN/AIIT

Title: Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis: A Prospective, Multicenter, Cohort Study (The Defier Study)

Brief Summary: Defier Study What is this study about? Femoropopliteal artery disease (a type of peripheral arterial disease) often requires stenting to restore blood flow to the legs. However, a common challenge after stenting is in-stent restenosis (ISR)-the treated blood vessel narrows again over time. Two advanced treatments for ISR are available: drug-coated balloons (DCBs) and drug-eluting stents (DESs). Both deliver medication to prevent vessel narrowing, but there is limited direct evidence comparing how well they work for ISR in the femoropopliteal artery (the main artery from the thigh to the knee).
This study (called the "Defier Study") aims to fill this gap by directly comparing the safety and effectiveness of DCBs and DESs for treating femoropopliteal ISR. The results will help doctors choose the best treatment for patients with this condition.
Who can take part in the study?
Eligible patients must:
Be 18 years or older and able to provide informed consent. Have symptoms of reduced blood flow to the legs (Rutherford class 2-5, e.g., pain when walking, rest pain, or skin changes).
Have a narrowed (≥50%) or blocked femoropopliteal stent (implanted more than 30 days earlier), with the affected area no longer than 30 cm.
Have at least one open blood vessel below the knee (to ensure blood flow after treatment).
Agree to attend follow-up visits for 2 years.
Patients will be excluded if:
They are pregnant/lactating, have severe vessel calcification that prevents treatment, or have acute limb ischemia/thrombosis.
They have a history of stroke in the past 60 days, contraindications to blood-thinning medications, or a life expectancy of less than 2 years.
How is the study conducted? This is a prospective, multicenter cohort study (observing patients over time) conducted at multiple university-affiliated hospitals in China. A total of 578 eligible patients will be enrolled over approximately 2 years.
Treatment assignment:
Doctors will choose either DCB or DES based on clinical judgment and real-world practice:
DCB group: The narrowed area is first expanded with a standard balloon, then treated with a paclitaxel-coated balloon (to deliver medication to the vessel wall). A bare-metal stent may be used if needed (e.g., if the vessel tears or remains too narrow after DCB treatment).
DES group: After initial balloon expansion, a paclitaxel-eluting stent (a stent that slowly releases medication) is implanted to cover the entire narrowed area.
Follow-up:
Patients will be checked at 1, 3, 6, 12, and 24 months after treatment. Tests will include ultrasound (to check vessel patency), ankle-brachial index (ABI, a measure of blood flow), and assessments of symptoms and adverse events.
What are the study's key goals?
Primary goal (main outcome):
To compare the rate of clinically driven target lesion revascularization (CD-TLR) at 24 months. CD-TLR means needing repeat procedures (e.g., balloon angioplasty or stenting) on the treated area because of worsening symptoms or reduced blood flow.
Secondary goals:
Rates of major adverse limb events (MALE, including major leg amputation).
Vessel patency (whether the treated area stays open):
Primary patency: The vessel remains open without repeat intervention. Secondary patency: The vessel stays open after additional interventions if needed.
Improvement in symptoms and blood flow (measured by ABI and Rutherford class). Stent fracture rate (for DES patients) and safety outcomes (e.g., 30-day death, bleeding, heart attack, or organ function decline).
Is the study safe and regulated? The study has been approved by the Medical Ethics Committee of the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine (Approval No. 2020KL-078) and follows the Declaration of Helsinki (international ethical standards for medical research).
It is registered on ClinicalTrials.gov (NCT04675632) and results will be published in a peer-reviewed medical journal.
Why is this study important? By directly comparing DCBs and DESs-two of the most advanced treatments for femoropopliteal ISR-this study will provide high-quality evidence to help doctors make better treatment decisions. For patients, this means more personalized, effective care that reduces the need for repeat procedures and improves quality of life.
For healthcare providers, the results will clarify which treatment works best for different patients (e.g., those with complex lesions) and optimize endovascular strategies for ISR.

开始日期2026-01-01

申办/合作机构

成都中医药大学

[+1]

100 项与成都中医药大学相关的临床结果

登录后查看更多信息

0 项与成都中医药大学相关的专利（医药）

登录后查看更多信息

6,983

项与成都中医药大学相关的文献（医药）

2026-12-31·ANNALS OF MEDICINE

Comparative effects of pharmacological interventions in the prophylactic treatment of tension-type headache: systematic review and network meta-analysis

Review

作者: Zheng, Hui ; Hua, Can ; Li, Xin-Yu ; Pantila, Kulachai ; Chen, Bo-Zhu ; Xie, Chao-Rong ; Lin, Li ; Mou, Jian-Jiao ; Wang, Zhen-Zhi ; Tao, Qing-Feng

BACKGROUND:

Tension-type headache (TTH) is the most common neurological disorder. The comparative effect of pharmacological interventions for TTH prophylaxis remains unclear. We aimed to assess the comparative effects of pharmacological interventions in the prophylactic treatment of TTH.

METHODS:

Ovid Medline, Embase, and Cochrane were searched from inception to 12 December, 2025. Randomized controlled trials (RCTs) of medications compared to placebo or another medication for preventing TTH were included. The primary outcome was headache days per month. A Bayesian random-effect model was employed as the primary analysis of chronic TTH.

RESULTS:

Thirty-five RCTs were included, 33 (88.6%) RCTs involved chronic TTH patients, and 24 RCTs provided available data for meta-analysis. Amitriptyline 100 mg presented more reduction of monthly headache days than placebo at 4 and 8 weeks (4 weeks: MD -6.59, 95% CrI -11.22 to -0.64; 8 weeks: MD -6.14, 95% CrI -10.27 to -0.87). BTX-A 100 U can reduce monthly headache days (MD -3.79, 95% CrI -7.16 to -0.33). Amitriptyline 100 mg was the highest-ranked treatment for monthly headache days at 4 (SUCRA 0.85), 8 (SUCRA 0.85), and 24 (SUCRA 0.87) weeks; 12 weeks was lidocaine 25 ml (SUCRA 0.75). Amitriptyline 100 mg and BTX-A 500 U showed a higher adverse event rate than placebo.

CONCLUSION:

Amitriptyline 100 mg and BTX-A 100 U may be options to reduce monthly headache days in patients with chronic TTH. Given the low to very low certainty of evidence, high risk of bias, and high heterogeneity, more studies are needed.

TRIAL REGISTRATION:

PROSPERO (CRD42025639586).

2026-12-01·MOLECULAR BIOLOGY REPORTS

Brown adipocytes from pluripotent stem cells: a promising therapy for obesity

Review

作者: Ma, Xiaoju ; Hu, Tingting ; Huang, Yan ; Rao, Chaolong ; Jiang, Jialuo ; Leng, Tian ; Chen, Yan ; Ha, Minggui

The identification of functional brown adipose tissue (BAT) and beige adipose tissue with significant thermogenic capabilities in adults has opened new avenues in the battle against obesity and its associated comorbidities.However, although obesity can be alleviated through strategies such as increasing physical activity, improving diet, and drug intervention, these methods all have inherent limitations, such as low compliance and obvious side effects. Consequently, there is an urgent need to investigate novel and effective methods for combating obesity. With ongoing advancements in stem cell technology, stem cell therapy has emerged as a promising strategy. Recent studies have demonstrated that certain pluripotent stem cells can differentiate into BAT under specific conditions and, when transplanted into mice, can elevate the animals' body temperature and metabolic rate. This suggests that pluripotent stem cells may represent a viable therapeutic option for addressing metabolic disorders such as obesity and diabetes. Owing to their distinct advantages, pluripotent stem cells have become the preferred choice for stem cell therapy in the treatment of obesity. This article will mainly focus on the differentiation process of pluripotent stem cells into brown adipocytes, as well as the application of gene editing technology in this field.

2026-04-01·TISSUE & CELL

The protective effect and mechanism of phycocyanin on diabetic retinopathy in rats

Article

作者: Li, Han ; Huang, Hongli ; Liu, Jinshen ; Shi, Fuju ; Zuo, Jiehui ; Wang, Linhong

Phycocyanin (PC), a bioactive pigment extracted from Spirulina, possesses multiple biological activities, including anti-inflammatory, antioxidant, and anticancer effects. The present study aimed to investigate the protective role of PC on the retina of diabetic rats and to elucidate its underlying mechanisms.Diabetes mellitus (DM) was induced in the model group (DM group) and the treatment group (PC group) by a single intraperitoneal injection of streptozotocin (STZ) at a dose of 55 mg/kg. After model establishment, the PC group received PC solution by daily oral gavage at a dose of 300 mg/kg for 12 consecutive weeks.Diabetic status was assessed by monitoring fasting blood glucose(FBG) levels, body weight, and general condition of the rats. Retinal histopathological changes were evaluated using hematoxylin and eosin H&E staining. Oxidative stress parameters, including catalase (CAT), superoxide dismutase (SOD), and glutathione (GSH), were measured using commercial biochemical assay kits. Reactive oxygen species (ROS) levels were determined by enzyme-linked immunosorbent assay (ELISA). Additionally, the expression of NRF2 and HO-1 proteins in retinal tissue was assessed by immunohistochemistry and Western blot analysis, while NRF2 and HO-1 mRNA expression levels were quantified using Real-Time PCR.The results indicated that PC administration did not significantly improve FBG or body weight in diabetic rats. However, PC markedly enhanced the activities of CAT, SOD, and GSH, reduced ROS accumulation, upregulated NRF2 and HO-1 protein expression, and attenuated oxidative stress-induced retinal injury in diabetic rats.

194

项与成都中医药大学相关的新闻（医药）

2026-01-31

·今日头条

The Innovation | 解锁乙肝相关肝癌免疫治疗新密码：CXCR6⁺耗竭T细胞成为关键驱动因子

肝细胞癌（Hepatocellular carcinoma, HCC）是全球第三大癌症死因，免疫检查点抑制剂（Immune checkpoint inhibitors, ICIs）虽带来希望，但响应率存在显著异质性。但是，临床观察到乙肝病毒（HBV）感染的HCC患者对免疫治疗的响应似乎优于非乙肝患者。因此，探索 HBV + HCC患者免疫治疗敏感性的核心机制，为“乙肝背景”HCC患者的精准免疫治疗提供新证据。导读 HCC是原发性肝癌最主要、最常见的类型，高发于中国、东亚和撒哈拉以南非洲等地区，乙肝病毒（HBV）感染是其主要风险因素之一。近年来，以PD-1/PD-L1抑制剂为代表的免疫治疗，显著改善了部分患者的长期生存并推动了肝癌系统治疗的进步。然而，患者临床应答差异巨大，导致大量患者承受高昂治疗费用却难以获益，这不仅加剧了患者经济与身心负担，也造成了医疗资源的浪费。因此，亟需通过深入研究揭示应答差异的机制，以推动肝癌的精准与分层治疗，使免疫治疗能真正惠及适合的患者群体。传统观点认为，慢性、长期HBV感染可能削弱机体免疫功能，然而临床数据却提示HBV + HCC患者的免疫治疗效果更优。现有研究发现，HBV 感染可能重塑肿瘤免疫微环境，但具体如何调控免疫治疗响应仍存在争议。本研究通过结合单细胞 RNA 测序、空间转录组、组织芯片等多组学技术及功能实验，首次揭示了乙肝相关HCC中独特的CXCL16 + 巨噬细胞与CXCR6 + PD1 + CD8 + T细胞轴在增强免疫应答中的关键作用，为合并有乙肝的HCC患者的免疫治疗注入了新的血液。图1 图文摘要 1 HBV + HCC患者免疫治疗优势显著研究团队首次证实HBV + HCC患者接受免疫治疗后，中位生存期显著延长（HBV + vs non-HBV，p=0.0049），肿瘤体积明显缩小，展现出更优的免疫治疗响应。更值得注意的是，HBV + 肿瘤微环境中CD8 + T细胞和巨噬细胞浸润密度均升高，且两者空间距离更近（图2 HBV相关肝癌患者接受免疫治疗的生存预后与影像学疗效评估 2 耗竭T细胞的“伪装者”——高毒性潜能亚群单细胞测序结果提示HBV + HCC患者肿瘤微环境中富集一种新型耗竭T细胞亚群 ——CD8 + PD-1 + CXCR6 + T细胞（命名为 TEX3）。该细胞虽处于耗竭状态，但保留强大的细胞毒性潜能，且对 PD-1 抑制剂高度敏感。多重免疫荧光实验证实HBV + 肝癌组织中CD8⁺PD-1⁺CXCR6⁺ T细胞密度更高。临床数据进一步揭示CD8⁺PD-1⁺CXCR6⁺ T细胞高富集的HCC患者对免疫治疗具有更显著的生存获益。这些发现表明CD8⁺PD-1⁺CXCR6⁺ T细胞可作为筛选HBV⁺肝癌免疫治疗获益人群的生物标志物，指导个性化治疗方案制定。图3 高毒性潜能TEX3亚群与患者免疫治疗生存获益的正相关性 3 CXCL16 + 巨噬细胞的“幕后推手”角色在乙肝相关HCC微环境中，CXCL16 + 巨噬细胞比例显著升高，它们通过分泌CXCL16趋化因子，特异性募集CXCR6 + PD1 + CD8 + T细胞至肿瘤区域，形成独特的免疫细胞协作网络，提示乙肝病毒可能通过改变肿瘤免疫微环境，意外地增强了免疫细胞的可重塑性。靶向CXCR6 + CD8 + T细胞联合PD-1抑制剂的治疗策略，在临床前模型中显示出协同抗肿瘤效果，为“免疫治疗+靶向干预”的联合方案提供了新思路。图4 CXCR6 + T细胞回输与抗PD-1疗法的强效协同作用总结与展望本研究首次绘制了HBV感染重塑肝癌免疫微环境的精细图谱，揭示 CD8⁺PD-1⁺CXCR6⁺ T细胞与 CXCL16⁺巨噬细胞的相互作用轴介导HBV + HCC患者免疫治疗响应的核心机制，解答了“乙肝相关HCC患者免疫治疗响应更佳”的临床问题。未来研究将进一步探索CXCR6/CXCL16轴在HCC免疫治疗中的预测价值，并推动相关联合疗法的临床转化，最终实现HCC的精准分层与个体化治疗。责任编辑梁涛山东省肿瘤医院周坤城成都中医药大学扫二维码｜查看原文原文链接：https://www.sciencedirect.com/science/article/pii/S2666675826000214 本文内容来自 Cell Press 合作期刊 The Innovation 第7卷以Article发表的“Hepatitis B virus-driven expansion of CXCR6 + exhausted T cells and CXCL16 + macrophage interaction: Implications for immunotherapy in hepatocellular carcinoma ” (投稿: 2025-08-31；接收: 2026-01-16；在线刊出: 2026-01-20)。 DOI : 10.1016/j.xinn.2026.101274 引用格式：Yang R., Lu C., Jian Q., et al. (2026). Hepatitis B virus-driven expansion of CXCR6 + exhausted T cells and CXCL16 + macrophage interaction: Implications for immunotherapy in hepatocellular carcinoma. The Innovation 7 :101274. 作者简介刘苏来，主任医师，博士生导师。湖南省人民医院学科建设部主任；数字化肝胆医疗湖南省工程研究中心主任；芙蓉实验室肝胆胰疾病研究中心主任；胆道疾病湖南省重点实验室副主任。中国医师协会外科医生分会肝胆青年专家工作组专家委员、中国医师协会肝癌专委会腹腔镜外科学组秘书兼委员、国际肝胆胰协会中国分会首届青年委员会常务委员；入选湖南省科技创新领军人才、湖南省卫生健康高层次学科带头人、中国科协优秀中外青年、湖湘青年英才等人才项目；长期从事肝胆肿瘤的外科临床与基础研究；主持国家自然科学基金面上项目，国家自然科学基金青年项目，湖南省杰出青年基金及湖南省优秀青年基金等省部级以上项目20余项。近五年以第1作者或通讯作者身份在JCO、The Innovation、Science Bulletin、Redox biology等国际医学领域著名学术期刊发表SCI论文30余篇。获得国家专利6项，国家软著权2项，并实现多项发明专利的成果转化。主编及参编《临床外科学》、《肝胆胰外科手术难点与攻克》、《老年肝胆胰手术难点与解决方案》等多部著作。创办新刊 April 16, 2026 The Innovation Drug Discovery is coming |《创新药物发现》即将创刊 April 27, 2026 The Innovation Oncology is coming |《创新肿瘤学》即将创刊 April 28, 2026 The Innovation Nutrition is coming |《创新营养》即将创刊 On the way The Innovation Neurology is Coming |《创新神经病学》即将创刊点击标题查看原文 The Innovation | Job Offer · 招聘编辑 The Innovation Call for Youth Editor--v2.0 青年编委招募点击标题查看原文往期推荐 HAIC联合靶向免疫治疗为肝癌术后复发高风险患者带来新曙光点击阅读机器学习策略发现HBV相关肝细胞癌预后新指标点击阅读人工智能是否能提升“癌王”胰腺癌早期检出率？点击阅读 AI助诊新突破：基于细胞学的深度学习揭秘未知原发癌症的起源点击阅读液体活检3.0：游离DNA追踪复杂疾病累及器官特定细胞群体的信号点击阅读首个复发/转移性腺样囊性癌临床实践指南发布，聚焦罕见肿瘤系统治疗点击阅读实体瘤BRAF基因突变临床诊疗国际专家共识点击阅读膀胱癌肿瘤微环境：分子机制与靶向治疗点击阅读结直肠癌精准治疗新机遇：医学图像的AI分析点击阅读中国的科学健康：数据与人工智能驱动的健康模式创新与实践点击阅读道阻且长: 我国消化道肿瘤药物研发现状与挑战点击阅读幽门螺杆菌感染对消化系统肿瘤免疫治疗疗效的影响点击阅读 “赘肉”真的一无是处？癌症患者中的“肥胖悖论” 点击阅读点燃肝内胆管癌“冷肿瘤”：从免疫逃避及肿瘤微环境切入点击阅读跨界融合：微纳结构限域下的光学检测与人工智能在疾病诊断中的创新应用点击阅读期刊简介扫二维码｜关注期刊官微 The Innovation 是一本由青年科学家与 Cell Press 于2020年共同创办的综合性英文学术期刊：向科学界展示鼓舞人心的跨学科发现，鼓励研究人员专注于科学的本质和自由探索的初心。作者来自全球81个国家；已被175个国家作者引用；每期1/5-1/3通讯作者来自海外。目前有200位编委会成员，来自22个国家；50%编委来自海外(含39位各国院士)；领域覆盖全部自然科学。The Innovation已被DOAJ, ADS, Scopus, PubMed, ESCI, INSPEC, EI, 中科院分区表(1区TOP), OARL等收录。2024年CiteScore为53.4；2024年影响因子为25.7(5 year lmpact Factor=40.2)。2023年6月25-28日，四本姊妹刊(The Innovation Life、The Innovation Geoscience、The Innovation Materials、The Innovation Medicine)联袂创刊；2024年2月26日，第五本姊妹刊The Innovation Energy出版创刊号。这五本姊妹刊已被Google Scholar, CAS, Scopus, DOAJ, OARL等数据库收录。2025年11月10日，第六本姊妹刊The Innovation Informatics出版创刊号。秉承“好文章，多宣传”理念，The Innovation刊群在海内外各平台推广作者文章。期刊官网： www.the-innovation.org www.cell.com/the-innovation 期刊投稿（Submission）： www.editorialmanager.com/the-innovation 商务合作（Marketing）： marketing@the-innovation.org Logo｜期刊标识 See the unseen & change the unchanged 创新是一扇门，我们探索未知；创新是一道光，我们脑洞大开；创新是一本书，我们期待惊喜；创新是一个“1”，我们一路同行。 The Innovation journals (2026) 能源科学第3卷第1期第7卷第1期生命科学第4卷第1期地球科学第4卷第1期材料科学第4卷第1期医学第4卷第1期 The Innovation journals (2020-2025) The Innovation刊群出版日合集 (2020-2025) 点击标题查看原文赞助单位

免疫疗法

2026-01-28

·小白云9761

重楼：深山中的"植物抗生素"

引言在云南高海拔的阴湿山林中，生长着一种被《神农本草经》誉为"蚤休"的珍贵药材——重楼。这味拥有1500余年药用历史的中药，因其"一茎独上，茎当叶心，叶凡二三层，每一层七叶"的独特形态而得名。作为云南白药、季德胜蛇药片、宫血宁胶囊等100多种中成药的核心原料，重楼正从传统草本走向现代生物医药的前沿，展现出"植物抗生素"般的广阔前景。 --- 一、传统功效：清热解毒的"要药" 核心药性重楼味苦，性微寒，有小毒，归肝经。这一药性特点决定了它在中医体系中的独特定位： - 清热解毒：针对热毒壅盛所致的疔疮痈肿、咽喉肿痛、痄腮等症 - 消肿止痛：缓解跌打损伤、关节肿痛、虫蛇咬伤引发的炎症疼痛 - 凉肝定惊：平息肝热，治疗小儿高热惊厥、癫痫抽搐经典配伍历代医家积累了丰富的应用经验： - 治乳痈：重楼9克配生姜3克，水煎兑白酒少许为引服，外敷芹菜泥 - 治喉痹：重楼根茎0.6克研末吞服，见效迅速 - 治扭伤：酒磨重楼浓汁涂擦伤处，日数次 --- 二、现代药理：多靶点的生物活性现代研究已从重楼中分离出320多个化合物，其中甾体皂苷（如重楼皂苷I-VII）是主要活性成分，占总皂苷含量50%以上。这些成分赋予了重楼多重药理作用： 1. 抗肿瘤作用重楼皂苷VI、VII能诱导肿瘤细胞凋亡（如肝癌、肺癌细胞），并抑制肿瘤血管生成。2024年成都中医药大学的研究证实，重楼皂苷通过调控PpTGA3转录因子影响其生物合成，为抗肿瘤药物开发提供了新靶点。截至2022年，重楼相关抗肿瘤专利申请已达514项。 2. 止血与创伤修复重楼通过促进血小板聚集和凝血因子活性，缩短凝血时间。临床研究显示，其可使凝血时间缩短30%。外用时能促进伤口修复和再生，这一特性使其成为外伤出血的常用药材。 3. 抗炎镇痛重楼皂苷可抑制炎症介质（如前列腺素E₂、组胺）释放，对关节炎、肌肉疼痛有显著缓解效果。其作用机制涉及NF-κB信号通路的调控。 4. 抗菌抗病毒体外实验表明，重楼提取物对金黄色葡萄球菌等致病菌及流感病毒具有抑制作用。2020年北京大学的随机对照试验显示，重楼表明，重楼提取物对金黄色葡萄球菌等致病菌及流感病毒具有抑制作用。2020年北京大学的随机对照试验显示，重楼提取物可使支气管炎患者咳嗽频率降低40%。 5. 神经保护对中枢神经系统具有镇静作用，能缓解小儿高热惊厥，契合传统"定惊"功效。最新研究还发现其具有保护大脑和肾脏的作用。 6. 心血管保护现代药理学证实，重楼具有改善心血管系统、降血脂、血糖及保护血管内皮细胞的作用。 --- 三、资源危机与可持续利用濒危现状重楼属植物繁殖周期长达5-7年，加上过度采挖，野生资源已濒临枯竭。成都中医药大学2024年发表在《Horticulture Research》（中科院一区TOP期刊）的综述指出，野生重楼种群因"繁殖周期长+过度采集"面临严峻挑战。科技破局 researchers are making breakthroughs: - 分子机制解析：鉴定出关键转录因子PpTGA3，发现水杨酸可通过该因子促进重楼皂苷合成 - 人工栽培推广：云南、四川等地已建立规范化种植基地，缓解野生资源压力 - 组织培养技术：通过细胞培养生产重楼皂苷，为未来工业化生产提供可能 --- 四、使用禁忌与安全警示尽管重楼功效显著，但其"有小毒"的特性要求严格辨证使用：禁用人群： 1. 虚寒证、阴性疮疡者：重楼性寒，易伤阳气 2. 孕妇：可能刺激子宫平滑肌，引起不良反应 3. 脾胃虚寒者：易引发腹痛、腹泻中毒症状：过量服用可引起恶心、呕吐、头晕、痉挛等，需严格控制用量（内服3-9克）。使用建议： - 严格遵医嘱，不可长期大量服用 - 外用鲜品需确保无农药污染 - 购买时选择正规渠道，注意重金属检测 --- 五、未来展望：从传统到现代重楼正经历从经验用药到精准医学的转型： 1. 抗肿瘤药物开发：基于重楼皂苷的靶向抗肿瘤药物已进入临床前研究 2. 妇科用药拓展：宫血宁胶囊等产品的成功，提示其在妇科疾病中的潜力 3. 国际认可：随着研究深入，重楼有望进入国际药典，成为天然药物的代表正如成都中医药大学黎胜红研究员团队所言，运用多组学技术结合分子遗传手段，将"全面解析重楼品质形成机理，为其资源开发与可持续利用奠定重要基础"。 --- 结语重楼这味"生于深山阴湿之地"的古老药材，正借助现代科学的力量焕发新生。从《神农本草经》的"去蛇毒"记载，到今天的抗肿瘤研究，它见证了中医药传承创新的历程。在保护与开发并重的理念下，这株"植物抗生素"将继续守护人类健康，书写新的药用传奇。

2026-01-20

·天然产物靶点发现

破解中药“黑箱”的国产原创利器：多靶标细胞膜色谱智筛分析仪

多靶标细胞膜色谱智筛分析仪（MCMC-ISW）代表了一种创新的“多对多”仿生二维色谱系统，巧妙地将“多靶点同步识别”与“智能筛查”集成在一起。在第一维度下，该仪器采用多靶细胞膜色谱模型，通过特定受体-配体相互作用从复杂的中医制剂中分离活性成分。随后，第二维度通过色谱柱切换技术与反相高效液相色谱（RP-HPLC）无缝结合，便于在线分离和鉴定这些活性化合物。专用数据库和智能分析系统随后实时整合和解读二维数据，从而阐明中医疗效的物质基础及其潜在的“多靶点、多途径”作用机制。此外，通过其完全自主、集成的设计，MCMC-ISW克服了关键技术挑战，包括并行多靶筛查和智能数据解卷，突破了高效机械膜固定和高通量筛查相关的技术瓶颈。该仪器整体为破译传统中医“黑匣子”提供了开创性的“中国解决方案”，最终为复杂系统研究开辟了新的智能时代。它有望成为一个稳健且先进的技术平台，深远推动中医现代化、创新药物发现和质量控制的发展。 MCMC-ISW的智能分析模块主要由三个组成部分组成：1）一个全面的TCM成分数据库GNDC，包含超过2.34亿种自然多样性的生物活性物质——包括232万种专用代谢物、2.2977亿肽序列、26万种碳水化合物和sRNA，并集成结构信息、生物活性和ADMET特性。这使得中药成分能够系统地分子层面表征。2）覆盖多种蛋白类型的目标结构库，如GPCR受体，辅以AlphaFold3等结构预测工具，为分子识别提供结构基础。利用这些数据和结构资源，开发出高通量分子对接平台。利用AutoDock Vina，系统地将38,000多个天然小分子与GPCR受体对接，生成结合能和构象数据，形成基于计算化学的先导候选物集。3）药物-靶向亲和力图序列融合框架（GSF-DTA）预测模型进一步优化了这一过程，通过从图结构和序列信息中提取和交叉积分特征。它能够高精度预测和排序药物-靶点亲和力，促进对大规模对接结果的智能且细致筛查。最终，选择具有最高潜在结合活性的候选分子，建立从高通量初步筛选到准确预测的完整计算分析流程。本研究开发的MCMC-ISW系统在药物筛查领域展现出显著优势，与传统表面等离子体共振（SPR）或生物层干涉测量（BLI）技术相比，具有多项突破性优势。与需要在芯片上固定靶点的SPR/BLI不同，这种方法通常限于单靶标，通量适中，可能失去原生靶标构象，且成本高昂，MCMC-ISW则利用细胞膜作为固定相。该策略更好地保留了目标蛋白的原生活性和构象，提供了更能反映生理条件的相互作用信息。它实现了从“靶点驱动”向“配体驱动”筛选的范式转变，能够直接从中医提取物和草药制剂等复杂系统中发现活性成分。该系统支持对多个目标（≥3）进行同时高通量筛查，核心消耗品可自我准备。色谱柱的疗效可持续>7天，且每个筛查周期的成本显著低于SPR/BLI筛查。 2025年10月16日，10月16日，四川省科协企业创新服务中心组织专家，对成都中医药大学、西安交通大学、海能技术共同研发的“多靶标细胞膜色谱智筛分析仪”项目进行了科技成果评价。该项目聚焦中药“多组分-多靶点”协同作用机制解析这一关键科学问题，成功研制出全球首台“多靶标细胞膜色谱智筛分析仪”，实现了从单一靶点向多靶点并行、从离线筛选向在线智能分析的重要跨越，为中药复杂体系的作用机理研究与质量控制提供了突破性解决方案。评价专家组由澳门科技大学原校长中国工程院院士刘良、香港浸会大学原校长中国科学院院士陈新滋、中国药科大学原副校长中国工程院院士王广基、香港大学教授欧洲科学院院士贾伟、原国家药品监督管理局副局长赵军宁、国家药典委员会首席科学家钱忠直、暨南大学教授叶文才、四川大学教授张志荣、中国医学科学院药用植物研究所所长张卫东、澳门大学教授王一涛、中国中医科学院研究员王继刚等组成。四川省中医药管理局党组书记、局长田兴军，成都中医药大学党委书记张泽钧，副校长国锦琳出席评价会。会议由四川省科协企业创新服务中心负责人何亨刚主持。王广基院士 “该仪器在全球范围内具有原创领先性，中国药科大学已引进两台。它在复杂中药体系成分分析中表现出色，能够化繁为简，显著提升后续药效研究的成功率。” 陈新滋院士 “该仪器不仅在功能上可精准捕捉复杂体系中的关键活性成分，外观设计也展现出专业品质，具备显著的出口潜力与市场吸引力。” 赵军宁研究员 “该成果为阐释中药复方制剂作为创新药的科学基础提供了关键技术支撑，响应了国家药品监管的重大需求，是中药现代化进程中的重要里程碑。” 贾伟院士用“令人振奋的突破”形容该成果，认为“这项研究真正实现了从复杂系统中捕捉关键信号，是打开中药‘作用黑箱’的关键工具。” 此外，多位专家指出，该仪器不仅在中药领域应用前景广阔，在天然产物筛选、药物研发、质量控制乃至环境检测等领域同样潜力巨大。张泽均书记该成果是学校坚持问题导向、推动学科交叉与协同创新的重要体现，学校将持续支持科研团队开展技术优化与成果转化工作。田兴军局长 “该成果不仅是中医药现代化进程中的重要突破，更是用现代科学解读中医药学原理的生动实践，对推动中医药国际化、服务健康中国建设具有战略意义。“多靶标细胞膜色谱智筛分析仪2025-I型”的成功研制，标志着以色谱为核心的中药复杂体系研究正式迈入“多成分-多靶标”智能化分析新阶段。该设备构建了“仪器—数据库—标准”一体化的技术生态链，为中药现代化与国际认证奠定了方法学基础，实现了从原创理论到自主可控高端科学仪器的重大跨越，高度契合国家推动中医药现代化与高端科学仪器自主发展的战略方向。 https://www.the-innovation.org/article/doi/10.59717/j.xinn-med.2026.100179

100 项与成都中医药大学相关的药物交易

登录后查看更多信息

100 项与成都中医药大学相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2026年02月08日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床申请批准

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

芪灯明目胶囊	黄斑水肿更多	临床2期
天丹定眩颗粒	梅尼埃病更多	临床申请批准
消腺止鼾口服液	腺样体肥大更多	临床申请批准
Tetrahydrofurofuranoid lignans	骨病更多	临床前
Ganoderma Lucidum Polysaccharide ( JAK2 x STAT3 )	缺血更多	临床前